China Life Private Equity is a private equity firm established in 2016 and located in Beijing, China. The firm specializes in equity investments, focusing on sectors such as life sciences, medical technology, healthcare services, and digital health. Through its investments, China Life Private Equity aims to support the growth and development of innovative companies within these industries.
SJ Semi is a MEOL foundry focused on front-end wafer manufacturing and quality systems. The company specializes in bumping, Cu pillar, RDL, and testing services for 12" wafers while investing in R&D for fan-out, TSV, interposer, and 3D technologies. With over a decade of experience, SJ Semi aims to support advancements in the semiconductor market.
Autolink
Series D in 2024
Autolink is involved in the automotive intelligence industry. They create a product portfolio centered on vehicle intelligence, SOA architecture, and multi-domain integration based on the central controller. They offer a single product that supports instrumentation, central control, copilot, rear seat entertainment, air conditioning control, the HUD, and surround view.
Xindi Digital Engineering System
Series D in 2024
Xindi Digital Engineering System specializes in the development of commercial software products for computer-aided design (CAD), focusing on 3D technology. The company creates CAD content compatible with a variety of systems, including AutoCAD, SolidWorks, CATIA, UG, Pro/E, Inventor, Solid Edge, Geomagic, Maya, and 3D Studio Max. By providing these solutions, Xindi enables manufacturing enterprises to efficiently establish comprehensive digital product development and design systems.
Weikaier Pharmaceutical Technology
Series C in 2024
Weikaier Pharmaceutical provides R&D of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals.
Astronergy
Series C in 2023
Astronergy is a manufacturing firm that specializes in the research, development, and production of solar modules to generate clean energy. Established in 2006, it is recognized as the first large-scale producer of high-efficiency thin film photovoltaic (PV) modules in mainland China. The company is a trusted provider of both monocrystalline and polycrystalline PV modules and focuses on creating high-efficiency crystalline silicon solar cells and modules. These products are designed for various applications, including utility-scale power stations, commercial and industrial PV systems, and residential PV systems. Astronergy aims to deliver high-quality and high-performance photovoltaic solutions to support the global transition to renewable energy.
Xindi Digital Engineering System
Series D in 2023
Xindi Digital Engineering System specializes in the development of commercial software products for computer-aided design (CAD), focusing on 3D technology. The company creates CAD content compatible with a variety of systems, including AutoCAD, SolidWorks, CATIA, UG, Pro/E, Inventor, Solid Edge, Geomagic, Maya, and 3D Studio Max. By providing these solutions, Xindi enables manufacturing enterprises to efficiently establish comprehensive digital product development and design systems.
Sunwoda Electric Vehicle Battery
Series B in 2023
Sunwoda Electric Vehicle Batter provides electric vehicle battery pack solutions for new energy vehicle companies through advanced lithium battery integration technology. They built the BMS with independent intellectual property rights by dedicating their entire ability to the R&D and manufacturing of electric car battery systems, and they also built up automatic production lines for cell sorting, modules, and battery packs.
Care Medical
Series C in 2023
Care Medical is a membrane science platform that focuses on blood purification and biopharmaceuticals.
Yingke Biopharmaceutical
Series B in 2023
Yingke Biopharmaceutical operates as a high-tech biopharmaceutical enterprise integrating R&D, production and sales.
VJTBio
Series C in 2023
VJTBio is a biopharmaceutical company specializing in high-end animal protein pharmaceuticals. The firm is dedicated to developing innovative treatments for animal health, with a particular emphasis on reproductive and immune health. By employing genetic recombination techniques, VJTBio focuses on creating biopharmaceuticals that enhance animal reproduction, prevent diseases, and promote overall pet health. In addition to its research and development efforts, the company is involved in the production and sales of these advanced treatments, offering clinical testing and technical services to the biopharmaceutical industry and medical professionals.
Svision
Series C in 2023
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment.
Fushoukang
Series C in 2022
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.
Maxvax Health
Series B in 2022
MAXVAX is focused on the development and commercialization of innovative vaccines, specifically targeting viral diseases such as rotavirus, shingles, and herpes. The company's technology is designed to enhance treatment options within the biotechnology industry, enabling healthcare professionals to offer improved solutions for patients suffering from these infections. By concentrating on effective vaccine development, MAXVAX aims to contribute significantly to the healthcare sector and improve patient outcomes.
Maxvax Health
Series B in 2022
MAXVAX is focused on the development and commercialization of innovative vaccines, specifically targeting viral diseases such as rotavirus, shingles, and herpes. The company's technology is designed to enhance treatment options within the biotechnology industry, enabling healthcare professionals to offer improved solutions for patients suffering from these infections. By concentrating on effective vaccine development, MAXVAX aims to contribute significantly to the healthcare sector and improve patient outcomes.
HanBang Technology
Series C in 2022
HanBang Technology is a company that focuses on the integration of research and development, production, and trade, with a primary emphasis on liquid chromatography products. In addition to this core offering, HanBang Technology manufactures and provides advanced 3D printing equipment tailored for the aerospace and electronics sectors. The company specializes in metal 3D printers and delivers comprehensive application solutions that utilize selective laser melting technology and multi-laser additive manufacturing. HanBang Technology also handles machine delivery and installation for industrial applications, positioning itself as a key player in both chromatography and additive manufacturing markets.
METiS Therapeutics
Series B in 2022
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Immunochina
Series D in 2021
ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.
Sinotau
Series D in 2021
SinoTau is a comprehensive solution provider focused on both generic and innovative pharmaceuticals. The company specializes in the early development of antibody biopharmaceuticals and conducts research on a range of medications aimed at treating cancers, neurological disorders, and autoimmune diseases. With expertise in medicinal chemical synthesis, generic drug analysis, and pharmaceutical preparations, SinoTau supports the biotechnology industry through targeted drug development. Their work is underpinned by advanced diagnostic technologies and monoclonal antibody innovations, positioning them as a key player in the fields of cardiovascular health, neurodegeneration, and oncology.
GeneQuantum Healthcare
Series C in 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company specializing in the research and development of innovative biotherapeutics, particularly in the field of anti-tumor therapies. Founded in August 2013 in Suzhou Industrial Park, the company has established a world-class bio-conjugation technology platform that utilizes a ligase-dependent conjugation method. This advanced technology significantly enhances the therapeutic window for developing a series of next-generation Antibody-Drug-Conjugates (ADCs). GeneQuantum is actively working on advancing its ADC candidates towards Investigational New Drug (IND) applications in both the United States and China, while also focusing on expanding its product pipeline to address unmet medical needs in cancer treatment.
Vazyme Biotech
Series C in 2020
Vazyme Biotech Co., Ltd. is a biotechnology company based in Nanjing, China, founded in 2012. The company specializes in the development and production of enzymes and antibodies, with applications across various fields including clinical diagnosis, molecular diagnostics, high-throughput sequencing, and life science research. Vazyme Biotech is recognized for its advanced research and development capabilities and employs cutting-edge technology to innovate within the biotechnology sector. Its strategic location in the National Economic and Technological Development Zone of Nanjing allows the company to leverage regional resources and expertise, positioning it to play a significant role in the national biotechnology landscape.
OPM Biosciences
Corporate Round in 2020
OPM Biosciences is a biotechnology company based in Shanghai that specializes in the development and production of serum-free media for culturing animal cells. The company offers cell culture solutions and provides comprehensive contract development and manufacturing organization (CDMO) services. By focusing on innovative products and services, OPM Biosciences aims to enhance the efficiency and effectiveness of cell culture processes in the biotechnology sector.
Harbour BioMed
Series B in 2018
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.
Wanka Online
Series C in 2018
Wanka Online Inc. is a technology company based in Beijing, China, specializing in android-based content distribution services. Founded in 2014, the company offers a range of services including mobile advertising, online video distribution, game co-publishing, and IT development. Its DAPG Platform utilizes advanced technologies such as data mining and analytics to help marketers effectively reach Android smartphone users in China. This platform enables targeted distribution of advertisements, games, and videos, allowing businesses to deliver personalized content through various mobile applications. Wanka Online primarily generates its revenue from mobile advertising services, connecting diverse industries to millions of smartphone users across the region.
Asia Bioenergy Technologies Berhad
Venture Round in 2013
Asia Bioenergy Technologies Berhad (ABT) is a Malaysia-based technology incubation and investment holding company. The Company operates in four business segments: technology incubation, which comprises the main business segments; biofuel related products, which includes the sale of compounds for use in biofuel processes; information technology, which is engaged in the provision of information technology training and related services and equipment and corporate services, and biotechnology products, which is engaged in the provision of biotechnology products and services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.